Remogliflozin etabonate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Remogliflozin etabonate (GSK189075) 是一种具有口服活性的，选择性和低亲和力的钠葡萄糖共转运蛋白 (SGLT2) 抑制剂，对 hSGLT2，rSGLT2，hSGLT1，rSGLT1 的 Ki 值分别为 1.95 μM，43.1 μM，2.14 μM，8.57 μM。Remogliflozin etabonate 是一种基于苄基吡唑葡糖苷的前体，在体内被代谢成其活性形式，瑞格列净 (Remogliflozin)。Remogliflozin etabonate 在啮齿动物模型中显示出抗糖尿病功效。

Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

——

Remogliflozin etabonate (GSK189075; 10 or 30 mg/kg; orally; twice daily for 6 weeks) significantly reduced both the FPG and GHb levels in a dosedependent manner. Remogliflozin etabonate (3, 10, 30 mg/kg; orally) increases urinary glucose excretion in a dose-dependent manner. Remogliflozin etabonate dose-dependently inhibits the increase in plasma glucose after glucose loading and decreases the plasma insulin in normal rats. Remogliflozin etabonate (1-10 mg/kg; orally) decreases the blood glucose and reduces the AUC0–6 h for blood glucose in a dose-dependent manner.Remogliflozin etabonate (high-fat diet containing 0.01, 0.03, or 0.1% remogliflozin etabonate for 8 weeks) reduces the levels of plasma glucose, plasma insulin, and GHb in a dose-dependent manner, and it suppresses the development of hypertriglyceridemia in male GK rats (6 weeks of age). Animal Model:db/db mice at the age of 8 weeks Dosage:10 or 30 mg/kg Administration:Orally; twice daily for 6 weeks Result:Significantly reduced both the fasting plasma glucose (FPG) and glycated hemoglobin (GHb) levels in a dosedependent manner. Reduced both urine volume and urinary glucose excretion with ameliorated the hyperglycemia.

——

GPCR/G Protein

SGLT

SGLT

——

——

442201-24-3

522.59

C26H38N2O9

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 100 mg/mL (191.35 mM; 超声助溶 )

CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years